Celltrion's Avtozma, a biosimilar to Actemra, was approved by the European Commission for sale in member states.

South Korean pharmaceutical firm Celltrion announced Monday that Avtozma, a biosimilar of Actemra, has received approval from the European Commission. The approval covers major indications of the ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for Avtozma® (CT-P47), a ...

Find earnings, economic, stock splits and IPO calendars to track upcoming financial events from Yahoo Finance.